NDAINJECTIONINJECTABLE
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPASTAT SULFATE (capreomycin sulfate) is an injectable antibiotic indicated for treatment of tuberculosis, particularly drug-resistant TB. It functions as a second-line agent that inhibits bacterial protein synthesis. This is a legacy product first approved over 50 years ago.
LOE Approaching
As an older TB therapy with LOE approaching, this product likely operates with a lean commercial team focused on maintaining specialty prescriber relationships and managing decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CAPASTAT SULFATE offers limited career growth opportunities as a legacy, off-patent TB antibiotic with no linked job postings identified. Roles are concentrated in specialty sales, operations, and compliance rather than innovation or commercial expansion.
Specialty Sales RepresentativeAccount Manager
Worked on CAPASTAT SULFATE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.